Li Haiyan, Mei Yunhua, Wang Ying, Xu Lingyun
Shanghai Institute of Immunology, Shanghai Jiao Tong University Medical School, Shanghai, PR China.
J Clin Immunol. 2006 Sep;26(5):430-7. doi: 10.1007/s10875-006-9042-2. Epub 2006 Sep 10.
Vasoactive intestinal peptide (VIP) has been found to act as a potent anti-inflammatory factor through regulating the production of both anti- and pro-inflammatory mediators and promoting Th2-type responses. In this study, we used myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis (EAE) model in C57BL/6 mice to investigate the potential effects of VIP on multiple sclerosis. Our results showed that in vivo treatment of EAE-induced mice with VIP had great protective benefit at both clinical and histological levels. Disease suppression was associated with the inhibition of T cells proliferation, shifting of the immune response toward a Th2-type response and influencing the expression of pro-inflammatory cytokines including IFN-gamma, IL-6 and IL-2 as well as chemotactic factors such as RANTES. In conclusion, the study provides evidence that VIP had great protective effect on EAE through its inhibition actions on pathogenic T cells and through a specific effect on the Th1 response.
血管活性肠肽（VIP）已被发现可通过调节抗炎和促炎介质的产生以及促进Th2型反应，发挥强大的抗炎因子作用。在本研究中，我们使用髓鞘少突胶质细胞糖蛋白诱导的C57BL/6小鼠实验性自身免疫性脑脊髓炎（EAE）模型，来研究VIP对多发性硬化症的潜在影响。我们的结果表明，在体内用VIP治疗EAE诱导的小鼠，在临床和组织学水平上均具有显著的保护作用。疾病抑制与T细胞增殖的抑制、免疫反应向Th2型反应的转变以及对包括IFN-γ、IL-6和IL-2等促炎细胞因子以及趋化因子如RANTES的表达影响有关。总之，该研究提供了证据表明，VIP通过对致病性T细胞的抑制作用以及对Th1反应的特定作用，对EAE具有显著的保护作用。
